Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy

References

• Alvarez RD, Sill MW, Davidson SA, et al. (2014). A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 133:433.
   PubMed Web of Science ®Google Scholar
• Boro M, Singh V. (2016). Mycobacterium tuberculosis-triggered Hippo pathway orchestrates CXCL1/2 expression to modulate host immune responses. Sci Rep 6:37695.
   PubMed Web of Science ®Google Scholar
• Casanova ML, Larcher F, Casanova B, et al. (2002). A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62:3402
   PubMed Web of Science ®Google Scholar
• Danhier F, Vroman B, Lecouturier N, et al. (2009). Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 140:166–73.
   PubMed Web of Science ®Google Scholar
• Egorina EM, Sovershaev MA, Osterud B. (2006). In-cell Western assay: a new approach to visualize tissue factor in human monocytes. J Thromb Haemost 4:614–20.
   PubMed Web of Science ®Google Scholar
• Fan L, Chen J, Zhang X, et al. (2014). Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. Gynecol Oncol 135:125–32.
   PubMed Web of Science ®Google Scholar
• Fimmel S, Devermann L, Herrmann A, Zouboulis C. (2007). GRO-: a potential marker for cancer and aging silenced by RNA interference. Ann NY Acad Sci 1119:176–89.
   PubMed Web of Science ®Google Scholar
• He ZY, Deng F, Wei XW, et al. (2016). Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex. Sci Rep 6:23764.
   PubMed Web of Science ®Google Scholar
• Kanhaiya K, Czeizler E, Gratie C, Petre I. (2017). Controlling directed protein interaction networks in cancer. Sci Rep 7:10327.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, et al. (2015). IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4:00.
   Web of Science ®Google Scholar
• Lammi C, Zanoni C, Arnoldi A. (2015). A simple and high-throughput in-cell Western assay using HepG2 cell line for investigating the potential hypocholesterolemic effects of food components and nutraceutics. Food Chem 169:59–64.
   PubMed Web of Science ®Google Scholar
• Li X, Xie Z, Xie C, et al. (2015). D-SP5 peptide-modified highly branched polyethylenimine for gene therapy of gastric adenocarcinoma. Bioconjugate Chem 26:1494.
   PubMed Web of Science ®Google Scholar
• Liang B, He M, Chan C, et al. (2009). The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials 30:4014–20.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang X, Lei Q, et al. (2015). PEG–PEI/siROCK2 protects against Aβ42-induced neurotoxicity in primary neuron cells for Alzheimer disease. Cell Mol Neurobiol 35:841–8.
   PubMed Web of Science ®Google Scholar
• Mao TL, Fan KF, Liu CL. (2017). Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Gene Ther 24:621–9.
   PubMed Web of Science ®Google Scholar
• Pan T, Khare S, Ackah F, et al. (2013). In vitro cytotoxicity assessment based on KC50 with real-time cell analyzer (RTCA) assay. Comput Biol Chem 47:113–20.
   PubMed Web of Science ®Google Scholar
• Papadimitriou K, Kountourakis P, Kottorou AE, et al. (2016). Follicle-stimulating hormone receptor (FSHR): a promising tool in oncology? Mol Diagn Ther 20:523–30.
   PubMed Web of Science ®Google Scholar
• Parkunan SM, Randall CB, Astley RA, et al. (2016). CXCL1, but not IL-6, significantly impacts intraocular inflammation during infection. J Leukoc Biol 100:1125–34.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Svoronos N, Rutkowski MR, et al. (2017). Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23:441–53.
   PubMed Web of Science ®Google Scholar
• Rauh-Hain JA, Birrer M, Del Carmen MG. (2016). Carcinosarcoma of the ovary, fallopian tube, and peritoneum: prognostic factors and treatment modalities. Gynecol Oncol 142:248–54.
   PubMed Web of Science ®Google Scholar
• Roshan Moniri M, Young A, Reinheimer K, et al. (2015). Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 67:379–86.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Liamptong P. (2015). Quantitative analysis of signal transduction with in-cell Western immunofluorescence assays. Methods Mol Biol 1314:115.
   PubMedGoogle Scholar
• Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. (2016). Precision targeted therapy of ovarian cancer. J Control Release 243:250–68.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149.
   PubMed Web of Science ®Google Scholar
• Staropoli N, Ciliberto D, Chiellino S, et al. (2016). Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. Oncotarget 7:82741–56.
   PubMedGoogle Scholar
• Tugyi R, Uray K, Ivan D, et al. (2005). Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 102:413–8.
   PubMed Web of Science ®Google Scholar
• Wang J, Lei Y, Xie C, et al. (2014). Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy. Bioconjugate Chem 25:414–23.
   PubMed Web of Science ®Google Scholar
• Xu W, Rush J, Rickett K, Coward JIG. (2016). Mucinous ovarian cancer: a therapeutic review. Crit Rev Oncol 102:26–36.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. (2014). Non-viral vectors for gene-based therapy. Nat Rev Genet 15:541–55.
   PubMed Web of Science ®Google Scholar
• Yu D, Lu Q, Xie J, et al. (2010). Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 31:2278–92.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen J, Zheng YF, et al. (2009). Follicle-stimulating hormone peptide can facilitate Paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69:6506–14.
   PubMed Web of Science ®Google Scholar